View On Demand

Adapting Innovative Sports Technology To Improve Millions Of Lives

About the Event

Heart Rate Variability (HRV) testing was developed by Omegawave to help world-class athletes recover more quickly and perform at their peak. Inmedix has an exclusive license to use this technology in healthcare.

Inmedix has adapted the next generation of HRV testing to measure stress biology as a diagnostic aid across a variety of conditions including rheumatology. The total addressable market for this breakthrough exceeds $3BN. 

Join our panel discussion to learn about the genesis of the technology and hear how Inmedix plans to roll out their HRV platform that 96% of rheumatologists surveyed say they need now.

Featured Panelists:

Dr. Andrew Holman, Founder and CEO, Inmedix
Andrew is the founding rheumatologist and Director of Research at Pacific Rheumatology Research Inc. He is former President of the Northwest Rheumatism Society and a Clinical Associate Professor of Medicine at the University of Washington. He has designed, completed and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.

Leslie Bottorff, Principal, Bottorff Advisors
Leslie works with CEOs and teams of MedTech companies to build new products and accelerate growth. She was Sr. Managing Director at GE Ventures where she led the healthcare investing team and an operating executive in the medical device industry. She has an MBA from Harvard Business School and  an Engineering degree from Purdue University. 

Val Nasedkin, VP, Omegawave
Val is one of the developers of Omegawave technology and the company’s VP of Business Development. He is an expert in physiological readiness as well as a former elite athlete and a current coach. He is also in the advisory board for the Nike Sparq athletic performance division.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.